Michael Martino

Michael Martino is currently Chairman and CEO of Ampio Pharmaceuticals Inc., a company focused on developing therapeutics for inflammatory indications and inflammatory conditions related to SARS-CoV-2. Prior to joining Ampio Pharmaceuticals Inc., Mr. Martino was the CEO of HemaFlo, a company focused on the development of a proprietary Drag Reducing Polymer technology (DRP) for the treatment of Acute Kidney Injury (AKI). Prior to HemaFlo, he was President, CEO and a member of the Board of Ambit Biosciences, a San Diego-based company focused on developing a drug to treat Acute Myeloid Leukemia, from November 2011 to November 2014. Under his leadership, Ambit initiated a large, multi-national Phase 3 study; secured $25 million in private financing; completed a $90 million IPO; and ultimately sold the company to a Daiichi Sankyo for $450 million in cash plus future milestone payments.